Literature DB >> 9310011

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis.

F A Sirgel1, F J Botha, D P Parkin, B W Van de Wal, R Schall, P R Donald, D A Mitchison.   

Abstract

The early bactericidal activity (EBA) of ciprofloxacin (CIP) was measured in 80 patients with previously untreated, smear-positive pulmonary tuberculosis by counting viable bacilli in sputum collections during the first 2 d of treatment. Groups of about 10 patients were treated daily with graded doses of CIP or with 300 mg isoniazid or with no drug. The mean EBA, defined as the fall in log CFU/ ml sputum/d, increased from -0.011 in the no drug group to 0.046, 0.092, 0.121, and 0.205 in the groups receiving 250, 500, 1,000, or 1,500 mg CIP, respectively, a highly significant trend. These results demonstrate the antimycobacterial activity of CIP in high dosage, though the mean EBAs of 0.55 and 0.66 in two groups receiving isoniazid were much higher.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310011     DOI: 10.1164/ajrccm.156.3.9611066

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

1.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

3.  Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors:  E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

6.  Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

Authors:  Veronique De Jager; Lize van der Merwe; Amour Venter; Peter R Donald; Andreas H Diacon
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 7.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

8.  Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; T P Kanyok; L H Danziger; A Venter; F J Botha; D P Parkin; H I Seifart; B W Van De Wal; J S Maritz; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation.

Authors:  Louis Grandjean; Laura Martin; Robert H Gilman; Teresa Valencia; Beatriz Herrera; Willi Quino; Eric Ramos; Maribel Rivero; Rosario Montoya; A Roderick Escombe; David Coleman; Denis Mitchison; Carlton A Evans
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

Review 10.  Drug treatment for tuberculosis during pregnancy: safety considerations.

Authors:  G Bothamley
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.